Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $5.67 Consensus PT from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned an average rating of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.67.

Separately, HC Wainwright dropped their price target on Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 1st.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics stock opened at $1.06 on Friday. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $3.87. The stock’s 50 day moving average is $1.32 and its 200 day moving average is $1.05. The firm has a market cap of $123.46 million, a P/E ratio of -0.85 and a beta of 0.03.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $33.75 million during the quarter, compared to analysts’ expectations of $33.50 million. During the same quarter in the previous year, the business posted ($0.43) earnings per share. Equities analysts anticipate that Karyopharm Therapeutics will post -1.19 earnings per share for the current fiscal year.

Insider Transactions at Karyopharm Therapeutics

In other news, CEO Richard A. Paulson sold 80,470 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $94,149.90. Following the transaction, the chief executive officer now directly owns 1,183,783 shares of the company’s stock, valued at $1,385,026.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Richard A. Paulson sold 80,470 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $94,149.90. Following the transaction, the chief executive officer now directly owns 1,183,783 shares of the company’s stock, valued at $1,385,026.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Mason sold 27,687 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total value of $32,393.79. Following the transaction, the chief financial officer now directly owns 404,918 shares in the company, valued at $473,754.06. The disclosure for this sale can be found here. Insiders have sold 171,331 shares of company stock valued at $206,118 over the last ninety days. 3.32% of the stock is owned by company insiders.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently bought and sold shares of the stock. Bleakley Financial Group LLC bought a new position in Karyopharm Therapeutics in the 4th quarter valued at $33,000. Simplicity Solutions LLC bought a new position in Karyopharm Therapeutics in the 4th quarter valued at $33,000. Wade G W & Inc. bought a new position in Karyopharm Therapeutics in the 3rd quarter valued at $60,000. SG Americas Securities LLC grew its stake in Karyopharm Therapeutics by 295.0% in the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock valued at $64,000 after purchasing an additional 54,839 shares during the period. Finally, Simplicity Wealth LLC bought a new position in Karyopharm Therapeutics in the 1st quarter valued at $66,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).